While the use of Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) for patients with DNA damage repair (DDR) mutations is well established for ovarian [17], breast [18] and pancreatic cancer [19], the first PARP inhibitors (PARPi) approved for PCa by the FDA occurred in 2020. This evidence concerns the gene PARP1 and pancreatic neoplasm.